1.Biliary ascariasis and extrahepatic cholangiocarcinoma.
Singapore medical journal 1995;36(5):570-570
2.Agenesis of the gall bladder with duplication cysts of the hepatic flexure--a case report and literature review.
Singapore medical journal 1993;34(2):181-182
A 24-year-old lady with recurrent upper abdominal pain, underwent surgery for cholelithiasis based on imaging diagnosis by ultrasound scanning. At laparotomy, the gall bladder could not be found either in its normal or ectopic locations. The diagnosis of agenesis of the gall bladder was confirmed by operative cholangiography. Duplication cysts of the hepatic flexure were discovered in the position normally occupied by the gall bladder. The stony hard faeces in the cysts were probably interpreted as gallstones on ultrasound. This rare condition is discussed and the importance of intraoperative cholangiography is stressed.
Adult
;
Cholelithiasis
;
diagnosis
;
Colonic Diseases
;
complications
;
pathology
;
Cysts
;
complications
;
pathology
;
Diagnosis, Differential
;
Female
;
Gallbladder
;
abnormalities
;
Humans
3.Anomalous pancreatico-biliary junction--a non-dilated biliary system and gallbladder carcinoma.
T F Toufeeq KHAN ; F Z HAYAT ; S MUNIANDY
Singapore medical journal 1998;39(1):25-26
Anomalous pancreatico-biliary junction (APBJ) is commonly associated with cystic dilatation of the bile ducts but recently, several cases without the cystic dilatation have been reported. We treated a young female patient with intractable back and epigastric pain of three months duration. The spine was normal on magnetic resonance imaging (MRI), but several lymph nodes were seen around the coeliac axis. An APBJ, a non-cystic biliary system, non-filling of the gallbladder and an irregular right margin of the bile duct were evident on endoscopic retrograde pancreatography (ERCP), which was highly suggestive of gallbladder (GB) malignancy. At surgery, the GB was hard with local infiltration of the bile duct. Numerous large para-aortic and supraduodenal lymph nodes were present and only a biopsy was possible. Details of the case are presented and the growing etiological importance of an APBJ, especially without cystic biliary dilatation in gallbladder carcinogenesis is discussed.
Adenocarcinoma
;
diagnosis
;
Adult
;
Cholangiopancreatography, Endoscopic Retrograde
;
Common Bile Duct
;
abnormalities
;
Female
;
Gallbladder Neoplasms
;
diagnosis
;
Humans
;
Magnetic Resonance Imaging
;
Pancreatic Ducts
;
abnormalities
4.Bilio-enteric anastomoses: results in benign and malignant conditions.
T F Toufeeq KHAN ; M LWIN ; S ULAH ; A ZAHARI ; I MOKTI
Singapore medical journal 1993;34(6):545-550
Twenty bilio-enteric anastomoses were performed or managed from May 1990 to December 1992. Recurrent pyogenic cholangitis (RPC) and pancreatic cancer were the commonest conditions which required drainage procedures. Roux-en-Y hepatico-jejunostomy (RHJ) was performed in 9 patients, 4 for RPC, one for pancreatic cancer, another for a cholangiocarcinoma, 2 following excision of choledochal cyst and one hepatico-jejunostomy was part of a Whipple reconstruction. Roux-en-Y side to side choledocho-jejunostomy (CDJ) was performed in one patient. Choledocho-duodenostomy (CDD) was performed in 6, 4 for obstructive jaundice due to choledocholithiasis, one for RPC and one in a choledochal cyst. One patient operated elsewhere presented with complications after a CDD. Palliative cholecysto-jejunostomy (CYJ) was carried out in 4 patients with pancreatic malignancy. All benign conditions were treated by hepatico-jejunostomy and choledocho-duodenostomy, while three patients with malignant conditions were treated by hepatico-jejunostomy. Permanent subcutaneous access loops were provided when recurrent problems were anticipated, 4 in RPC and one after subtotal resection of a cholangiocarcinoma. Based on this study, we found Roux-en-Y hepatico-jejunostomy a versatile drainage procedure, which was useful in both benign and malignant diseases.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Anastomosis, Roux-en-Y
;
Anastomosis, Surgical
;
methods
;
Child
;
Cholecystostomy
;
Choledochostomy
;
Common Bile Duct
;
surgery
;
Common Bile Duct Diseases
;
surgery
;
Female
;
Follow-Up Studies
;
Hepatic Duct, Common
;
surgery
;
Humans
;
Intestine, Small
;
surgery
;
Male
;
Middle Aged
;
Pancreatic Neoplasms
;
surgery
;
Retrospective Studies
;
Treatment Outcome
5.Structural confirmation of sulconazole sulfoxide as the primary degradation product of sulconazole nitrate
Qun XU ; Khan ASHRAF ; Di GAO ; Adams M. KRISTIE ; Tadjimukhamedov FATKHULLA ; Shane TAN ; Simpson T. JOHN
Journal of Pharmaceutical Analysis 2018;8(2):96-102
Sulconazole has been reported to degrade into sulconazole sulfoxide via sulfur oxidation; however, structural characterization data was lacking and the potential formation of an N-oxide or sulfone could not be excluded. To clarify the degradation pathways and incorporate the impurity profile of sulconazole into the United States Pharmacopeia–National Formulary (USP–NF) monographs, a multifaceted approach was utilized to confirm the identity of the degradant. The approach combines stress testing of sulco-nazole nitrate, chemical synthesis of the degradant via a hydrogen peroxide-mediated oxidation reaction, semi-preparative HPLC purification, and structural elucidation by LC―MS/MS and NMR spectroscopy. Structural determination was primarily based on the comparison of spectroscopic data of sulconazole and the oxidative degradant. The mass spectrometric data have revealed a McLafferty-type rearrange-ment as the characteristic fragmentation pathway for alkyl sulfoxides with aβ-hydrogen atom, and was used to distinguish the sulfoxide from N-oxide or sulfone derivatives. Moreover, the generated sulco-nazole sulfoxide was utilized as reference material for compendial procedure development and valida-tion, which provides support for USP monograph modernization.
6.Flexor Hallucis Longus Transfer And V-Y Plasty: An Effective Treatment Modality for Chronic Achilles Rupture - A Case Series
Rashid RH ; Ali R ; Zahid M ; Ali M ; Ahmad T
Malaysian Orthopaedic Journal 2023;17(No.3):59-65
Introduction: To assess outcomes of FHL transfer and V-Y
plasty for chronic Achilles rupture due to insertional Achilles
tendinopathy.
Materials and methods: A case series of 12 patients was
conducted between 1st January 2017 and 31st December
2018. The patients had short flexor hallucis longus tendon
transfer with gastrocnemius lengthening by V-Y plasty for
Achilles tendon rupture. Patients were allowed full weight
bearing at six weeks post-operatively, and were followed up
at three months and six months post-operatively, when the
range of motion of the ankle was examined, and the outcome
was assessed using the EFAS score.
Results: Of the 12 patients in the study, the majority were
males; the mean age was 50.6±8.96 years. A significant
improvement in dorsiflexion and plantarflexion was noted at
the six-month follow-up compared to the three-month
follow-up (P=<0.001 for both). When compared to the
normal side, dorsiflexion and plantarflexion of the affected
ankle were significantly less at three months but were
comparable at six months post-operatively. A significant
improvement was noted in the mean EFAS score at the sixmonth follow-up (25.5±5.71) compared to three months
(18.6±0.90) post-surgery (P=0.001). Males were also noted
to have significantly higher EFAS scores at their six-month
follow-up than females (P=0.022). In contrast, a negative
correlation was noted between the European Foot and Ankle
Society (EFAS) score at the final follow-up and age
(P=0.011).
Conclusion: FHL tendon transfer with V-Y plasty in chronic
Achilles rupture due to insertional Achilles tendinopathy is
an effective procedure resulting in the restoration of the
ankle range of motion and improvement in functional scores.
7.Fagonia cretica: Identification of compounds in bioactive gradient high performance liquid chromatography fractions against multidrug resistant human gut pathogens
Tabassum, T. ; Rahman, H. ; Tawab, A. ; Murad, W. ; Hameed, H. ; Shah, S.A.R. ; Alzahrani, K.J. ; Banjer, H.J. ; Alshiekheid, M.A.
Tropical Biomedicine 2022;39(No.2):185-190
Plants are alternative source of natural medicines due to secondary active metabolites. Fagonia cretica
extracts and Gradient High-Pressure Liquid Chromatography fractionations were checked against
multidrug-resistant gastrointestinal pathogens including, Salmonella typhi, Escherichia coli and Shigella
flexneri. ESI-MS/MS analysis of bioactive HPLC fractions was performed to elucidate antibacterial
compounds. F. cretica extracts exhibited potential antibacterial activity. Twenty-four (24) HPLC fractions
were obtained from methanol, ethanol and aqueous extracts of F. cretica. Eighteen (18) fractions showed
antibacterial activity, while no activity was observed by the remaining six (6) fractions. HPLC fractions,
F1 (25g ± 0.20 mm) and F2 (15f
± 0.12 mm) of aqueous extract exhibited activity against multidrug
resistant GI pathogens. Gallic acid, quinic acid, cyclo-l-leu-l-pro, vidalenolone, liquirtigenin, rosmarinic
acid and cerebronic acid were identified in F1 fraction of aqueous extract, while succinic acid, cyclo (l-Leul-Pro) and liquirtigenin were identified in F2 fraction of aqueous extract through ESI-MS/MS analysis.
F. cretica extracts and HPLC fractions showed potential activity against MDR GI pathogens. Vidalenolone,
Cyclo-1-leu-1-pro and Cerebronic acid are first time reported in F. cretica. Further characterization of
bioactive compounds from F. cretica may be helpful to elucidate antibacterial therapeutic molecules.
8.Seroprevalence of low avidity anti-Toxoplasma IgG in pregnant women and its relationship with their age and contact with cats
Khan, K. ; Khan, W. ; Khan, T. ; Naaz, G. ; Naheda, A. ; Aqeel, S.
Tropical Biomedicine 2020;37(No.4):1038-1049
Toxoplasma gondii is a protozoan parasite that can infect all mammals, serving as
intermediate hosts. The cause of congenital toxoplasmosis is transplacental transmission of
the parasite to the foetus, resulting in wide range of manifestations from mild chorioretinitis
to miscarriage. Its frequency can be reduced by early screening of pregnant women which is
based mainly on tests for anti-Toxoplasma antibodies. We collected serum samples of 594
pregnant women (subjects) after taking their consent over a period of two years (2016-2018)
and analyzed them for anti-Toxoplasma IgG by ELISA. The positive samples were then
analyzed for IgG avidity test which could differentiate between recent and past infections.
The seroprevalence was also correlated with the age of the subjects and their contact with
cats. 162 subjects were found positive out of which only three showed a recent infection.
After following up until delivery, one of them delivered a baby who had jaundice and was
diagnosed with anti-Toxoplasma IgM at birth. The foetus of the second subject died in-utero,
while the third woman delivered a normal baby after being given spiramycin when diagnosed
with toxoplasmosis in the first trimester. It was found that most of the positive subjects had
frequent contact with cats. Invasion of the parasite during third trimester resulted in death
in-utero and jaundice. Most common cause of pregnancy wastage during our study was
spontaneous abortions while pregnancy loss due to congenital anomalies was rare.
9.Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
Mark Steven MILLER ; Peter J. ALLEN ; Powel H. BROWN ; Andrew T. CHAN ; Margie L. CLAPPER ; Roderick H. DASHWOOD ; Shadmehr DEMEHRI ; Mary L. DISIS ; Raymond N. DUBOIS ; Robert J. GLYNN ; Thomas W. KENSLER ; Seema A. KHAN ; Bryon D. JOHNSON ; Karen T. LIBY ; Steven M. LIPKIN ; Susan R. MALLERY ; Emmanuelle J. MEUILLET ; Richard B.S. RODEN ; Robert E. SCHOEN ; Zelton D. SHARP ; Haval SHIRWAN ; Jill M. SIEGFRIED ; Chinthalapally V. RAO ; Ming YOU ; Eduardo VILAR ; Eva SZABO ; Altaf MOHAMMED
Journal of Cancer Prevention 2021;26(1):71-82
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
10.Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
Mark Steven MILLER ; Peter J. ALLEN ; Powel H. BROWN ; Andrew T. CHAN ; Margie L. CLAPPER ; Roderick H. DASHWOOD ; Shadmehr DEMEHRI ; Mary L. DISIS ; Raymond N. DUBOIS ; Robert J. GLYNN ; Thomas W. KENSLER ; Seema A. KHAN ; Bryon D. JOHNSON ; Karen T. LIBY ; Steven M. LIPKIN ; Susan R. MALLERY ; Emmanuelle J. MEUILLET ; Richard B.S. RODEN ; Robert E. SCHOEN ; Zelton D. SHARP ; Haval SHIRWAN ; Jill M. SIEGFRIED ; Chinthalapally V. RAO ; Ming YOU ; Eduardo VILAR ; Eva SZABO ; Altaf MOHAMMED
Journal of Cancer Prevention 2021;26(1):71-82
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.